QUEBEC, Dec. 14 /CNW Telbec/ - Victhom Human Bionics Inc. (Victhom,
TSX: VHB) announced today the first implantation of its Neurostep(TM), a fully
implantable neuromodulation device, in a patient suffering from foot drop
secondary to a stroke. The first patient to receive the treatment was enrolled
at the Vancouver General Hospital in Vancouver, Canada.
This implantation is the first in a clinical study which will evaluate
the safety and performance of Victhom's Neurostep(TM) product at centers in
Europe, Canada, and India. "The start of this clinical evaluation represents
the latest step in the commitment of Victhom to the commercial development of
this important product for foot drop patients", stated Benoit Huet, President
and CEO of Victhom.
"Treatment of foot drop is a significant unmet need for patients
suffering from stroke, multiple sclerosis, cerebral palsy and spinal injury.
The implantation of the first patient is a major milestone for Victhom. We are
very pleased with the achievement of this milestone and look forward to the
completion of patient enrollment during the first half of 2008", added
Nader Kameli, Chief Operating Officer of Victhom's Neurobionix division. He
further commented that "Neurostep(TM) employs our proprietary technology for
closed-loop neuromodulation to address the challenges that these patients face
on a daily basis. Positive results of the Neurostep(TM) for this indication
could significantly improve the quality of life for this group of patients by
helping them to regain control in a fully automated fashion, similar to their
Victhom discovers, develops and manufactures bionic devices involved in
the treatment of a variety of physical and physiological dysfunctions.
Victhom's Neurobionix business unit focuses on the development and
commercialization of technologies and products involving implantable devices
that feature neurosensing and neurostimulation components, integrated with
artificial intelligence. Victhom's Biotronix business unit develops
biomechatronic products to support or replace peripheral limbs in what is
known as the orthotics and prosthetics market.
Some of the statements made herein may constitute forward-looking
statements. These statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and other
factors that may cause Victhom's actual results, performance or achievements
to be materially different from those expressed or implied by any of Victhom's
statements. Actual events or results may differ materially. We disclaim any
intention, and assume no obligation, to update these forward-looking
For further information:
For further information: Mr. Benoit Huet, President & CEO, Victhom Human
Bionics, (418) 872-5665, Fax: (418) 872-6926; firstname.lastname@example.org; Source:
Victhom Human Bionics Inc.